ATHE vs. JSPR, OSTX, COYA, HLVX, MNOV, XFOR, IMUX, EDIT, ABOS, and ORMP
Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Jasper Therapeutics (JSPR), OS Therapies (OSTX), Coya Therapeutics (COYA), HilleVax (HLVX), MediciNova (MNOV), X4 Pharmaceuticals (XFOR), Immunic (IMUX), Editas Medicine (EDIT), Acumen Pharmaceuticals (ABOS), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry.
Alterity Therapeutics vs.
Jasper Therapeutics (NASDAQ:JSPR) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends.
Jasper Therapeutics received 40 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 89.80% of users gave Jasper Therapeutics an outperform vote while only 66.67% of users gave Alterity Therapeutics an outperform vote.
79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 2.7% of Jasper Therapeutics shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Jasper Therapeutics had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 2 mentions for Jasper Therapeutics and 1 mentions for Alterity Therapeutics. Jasper Therapeutics' average media sentiment score of 0.89 beat Alterity Therapeutics' score of -0.50 indicating that Jasper Therapeutics is being referred to more favorably in the media.
Jasper Therapeutics presently has a consensus target price of $67.75, indicating a potential upside of 1,074.18%. Alterity Therapeutics has a consensus target price of $6.00, indicating a potential upside of 81.54%. Given Jasper Therapeutics' higher possible upside, research analysts clearly believe Jasper Therapeutics is more favorable than Alterity Therapeutics.
Alterity Therapeutics' return on equity of 0.00% beat Jasper Therapeutics' return on equity.
Jasper Therapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
Summary
Jasper Therapeutics beats Alterity Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Alterity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alterity Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ATHE) was last updated on 1/21/2025 by MarketBeat.com Staff
